SCHEMBL25595697

SCHEMBL25595697

COC1CCN(C(=O)NC(C)(C)C)C1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 1/20 0.59
LMNA P02545 3/20 0.54
VNN1 O95497 2/20 0.36
DPP4 P27487 1/20 0.35
KMT2A Q03164 2/20 0.35
NPC1 O15118 1/20 0.35
RAB9A P51151 1/20 0.35
KDM4E B2RXH2 1/20 0.34
ALDH1A1 P00352 1/20 0.34
MAPT P10636 1/20 0.34
POLB P06746 2/20 0.34
PRMT5 O14744 1/20 0.33
CSNK1E P49674 1/20 0.33
RORC P51449 1/20 0.33
LRRK2 Q5S007 1/20 0.33
MMP1 P03956 1/20 0.33
MMP13 P45452 1/20 0.33
KCNQ3 O43525 1/20 0.33
KCNQ2 O43526 1/20 0.33
KCNQ4 P56696 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13873069 0.90 SMN1; SMN2 (0.68) SMN1; SMN2LMNADPP4KMT2ANPC1
SCHEMBL24814982 0.86 SMN1; SMN2 (0.53) SMN1; SMN2LMNACSNK1ERORCKCNQ3
SCHEMBL18754890 0.85 SMN1; SMN2 (0.54) SMN1; SMN2LMNADPP4KMT2APOLB
SCHEMBL19011774 0.83 SMN1; SMN2 (0.51) SMN1; SMN2LMNADPP4KMT2ARAB9A
SCHEMBL19011564 0.81 SMN1; SMN2 (0.50) SMN1; SMN2LMNADPP4KMT2APOLB
SCHEMBL22996454 0.81 POLB (0.48) SMN1; SMN2LMNAVNN1KMT2ANPC1
SCHEMBL22182484 0.81 POLB (0.48) SMN1; SMN2LMNAVNN1KMT2ANPC1
SCHEMBL22996452 0.81 POLB (0.48) SMN1; SMN2LMNAVNN1KMT2ANPC1
SCHEMBL24158945 0.79 VNN1 (0.38) SMN1; SMN2LMNAVNN1DPP4KMT2A
SCHEMBL20837002 0.79 VNN1 (0.38) SMN1; SMN2LMNAVNN1DPP4KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230167110-A1 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS SCHRÖDINGER, INC. 2023-06-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230167110-A1 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS JAK2, JAK3, STAT5B SMN1; SMN2 4718/4885LMNA 4393/4885VNN1 3862/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.